Research Reports

Prepared Highlights

Gross business awards totaled $3.0 billion, up mid-single digits year-over-year, broad-based across large, midsized, and biotech customers with strength in oncology, cardiometabolic disease, and FSP (CEO).
Revenue was $2.043 billion in Q3 2025, up 0.6% year-over-year and up ~1.3% sequentially; therapeutic mix drove strong pass-through revenues (CFO).
Adjusted gross margin was 28.2%, down 10 bps sequentially from Q2 2025 and down from 29.5% in Q3 2024 (CFO).
Adjusted EBITDA margin was 19.4%, a 20 bps sequential decline from Q2 2025; adjusted EBITDA was $396.7 million, up $0.7 million sequentially (CFO).
Free cash flow was $333.9 million in Q3, bringing year-to-date total to $687.2 million (CFO).
Net book-to-bill was 1.02x, negatively impacted by elevated cancellations of $900 million, broadly flat with Q2 levels (CEO).
Share repurchases totaled $250 million in Q3 at an average price of $175 per share; year-to-date repurchases reached $750 million (CFO).
Adjusted EPS was $3.31, up 1.5% sequentially from Q2 2025, down 1.2% year-over-year (CFO).
Customer concentration: Top 5 customers = 24.6% of revenue, top 10 = 39.8%, top 25 = 66.6% (CFO).
Leverage ratio: 1.8x net debt to adjusted trailing 12-month EBITDA; net debt of $2.9 billion (CFO).
Cash and debt: Cash $468.9 million, debt $3.4 billion at September 30, 2025 (CFO).
Burn rate was flat sequentially at 8.2% in Q3 (CEO).

Official Guidance

Full-year 2025 revenue: $8.05 billion to $8.1 billion (CEO).
Full-year 2025 adjusted EPS: $13.00 to $13.20 (CEO).
Full-year 2025 adjusted effective tax rate: ~16.5% (CFO).

Mgmt Quotes

"Our performance was broadly in line with expectations as we successfully navigated a mixed market characterized by known challenges and emerging opportunities." (CEO)
"While recent cancellation levels are a headwind to revenue growth in the immediate term, ICON's global scale, industry-leading capabilities and financial strength provide us with an excellent platform for growth." (CEO)
"The recent demand dynamics provide significant grounds for optimism regarding the midterm trajectory as we move beyond a period of volatility and return to normalized levels of growth." (CEO)
"We made significant share repurchases in quarter 3, totaling $250 million at an average price of $175 per share, bringing our total share repurchases year-to-date to $750 million." (CFO)
"Our balance sheet position remains very strong, which affords us the flexibility to continue to strategically deploy capital." (CFO)

Prepared Metrics

Metric	Value	Speaker/Context
Revenue	$2.043 billion	Q3 2025, up 0.6% YoY, up ~1.3% sequentially (CFO)
Adjusted Gross Margin	28.2%	Q3 2025, down 10 bps sequentially (CFO)
Adjusted EBITDA Margin	19.4%	Q3 2025, down 20 bps sequentially (CFO)
Adjusted EPS	$3.31	Q3 2025, up 1.5% sequentially (CFO)
Free Cash Flow	$333.9 million	Q3 2025; YTD $687.2 million (CFO)
Gross Business Awards	$3.0 billion	Q3 2025, up mid-single digits YoY (CEO)
Net Book-to-Bill	1.02x	Q3 2025 (CEO)
Cancellations	$900 million	Q3 2025, broadly flat with Q2 (CEO)
Share Repurchases	$250 million	Q3 2025 at avg $175/share; YTD $750 million (CFO)
Net Debt	$2.9 billion	At Sept 30, 2025 (CFO)
Leverage Ratio	1.8x	Net debt to adjusted trailing 12-month EBITDA (CFO)
Burn Rate	8.2%	Q3 2025, flat sequentially (CEO)

Q&A Batch (1-5 of 13)

Q1 — Elizabeth Anderson

Topic: 取消订单动态及未来趋势
Key points:
- 取消量符合2Q电话预览；涉及集团多个领域，部分大型药企取消显著。
- 取消订单中以Q3前授予、但入组前取消的研究为主（非在研项目），相对较好。
- 管理层预计全年情况类似，2026年将逐渐缓和；认为当前接近高水位尾声。
Mgmt stance: 中性偏谨慎，因短期维持类似条件但预期中期改善。

Q2 — Justin Bowers

Topic: 行业环境分化（大型药企 vs 生物技术）及监管政策影响
Key points:
- 生物技术融资Q3有改善信号；TrumpRx与药企互动后市场积极反应。
- 政策一致性（无论好坏）对行业有利；RFP流量出现双位数增长，近期毛订单成功。
- 但领先指标传导至收入/利润仍有滞后，前两年波动影响尚未消化完。
Mgmt stance: 乐观但有保留（encouraging but mixed），因部分指标改善但整体环境仍不确定。

Q3 — Jailendra Singh

Topic: 竞争定价环境恶化程度及驱动因素
Key points:
- 定价环境未进一步恶化；2025年比以往更具竞争性但季度间未持续恶化。
- 压力主要来自大型药企客户，生物技术客户更关注价格可预测性。
- 竞争对手活动增加，因市场整体规模较小导致竞争更激烈。
Mgmt stance: 中性，认为环境仍高度竞争但未加剧，公司不通过低价获胜。

Q4 — Patrick Donnelly

Topic: 2026年利润率影响（传递项、定价）及潜在抵消因素
Key points:
- 传递项占比增加是2026年利润率拖累因素；定价环境更紧对明年影响大于今年。
- 抵消因素包括ICON历史成本管理、技术投资提升效率。
- 具体利润率指引将在2026年1月/2月提供，目前不给出方向。
Mgmt stance: 谨慎，拒绝提供2026年量化指引，等待进一步分析。

Q5 — Jack Meehan

Topic: 传递项占收入比例变化及毛利率底部（27%是否为底部）
Key points:
- 公司不拆分传递项与直接费用收入，仅提供定性描述（比例上升）。
- 心代谢领域RFP和订单量同比增长超一个数量级，该领域传递项负荷高，影响毛利率。
- 不评论27%是否为毛利率底部，将在2026年初设定指引时确认。
Mgmt stance: 谨慎，避免给出任何量化预期，强调业务组合因素复杂。

Q&A Batch (6‑10 of 13)

Q6 — Eric Coldwell

Topic: 非合同订单在 backlog/bookings 中的比例及取消来源
Key points:
- 公司一贯在拿到 awards 时就计入 bookings，而非等合同签署，因为 awards 到合同签收有数月滞后，此举更能反映实时商业需求。
- 取消主要发生在尚未进入 enrollment 的 awards 中（包含已签和未签合同），但管理层未给出二者具体占比。
- 取消原因还是过去几个季度提到的 biotech 融资困难、大型药企优先级调整等。
Mgmt stance: 中性；承认取消高于常态，但无法区分具体比例，强调这是行业整体现象。

Q7 — Charles Rhyee

Topic: backlog 质量、剩余取消风险、biotech RFP 流与 Win rate
Key points:
- 管理层认为更接近取消周期尾声而非开端，新进 backlog 的 awards 质量更健康。
- Biotech RFP 流显著增加（季度环比、同比、T12 均大幅增长），但 Win rate 环比基本持平，ICON 在该领域仍有机会提升。
- 部分 biotech 客户开始将资金投入大型、深度开发周期研究，可能偶尔导致更大规模取消。
Mgmt stance: 中性偏 bullish；对取消正常化和新订单质量有信心，但明确指出 biotech win rate 需改善。

Q8 — Michael Ryskin

Topic: 定价与 pass‑through 组件的短期性/结构性，以及何时正常化
Key points:
- 定价环境“稳定”但竞争激烈，管理层认为这是上游因素（监管、地缘政治、LOE、融资）的反映。
- 不会预测 1‑2 年后的定价，但随资金、监管和政治清晰度提高，行业有望逐步回归正常水平。
- 强调更高效药物开发（流程改进、技术部署）会推高总体研发支出，而非压低。
Mgmt stance: 中性；承认短期无明确正常化时间表，但长期看好行业支出增长。

Q9 — David Windley

Topic: 如何在劳动力稳定性与防御性利润率之间平衡
Key points:
- 当季员工人数变动仅约 100 人（总 40,000 人），离职率接近历史低位（自 COVID 高峰后持续下降）。
- 公司通过算法化资源管理在全 portfolio 分散风险，即使有大额研究暂停/取消也未导致劳动力或利润率大幅波动。
- 管理层不认为这是“margin vs bookings”的权衡，核心是优化资源配置、保持顶尖人才。
Mgmt stance: bullish；强调劳动力稳定与客户满意度可兼得，且公司已在多轮波动中证明了韧性。

Q10 — Kyle Crews

Topic: 2026 年取消风险是否仍高，以及 BARDA 资助的 COVID 试验更新
Key points:
- COVID 收入仅占 1%–2%（全年预测），不存在断崖式下降风险，甚至可能略升。
- 管理层预计 2026 年取消将回归正常水平，但不承诺从 1 月 1 日起线性下降；第四季度仍可能维持高位。
- 判断依据：对 backlog 的解读、客户沟通、行业需求动态，认为自己已处于“第九局”而非“第一局”。
Mgmt stance: bullish（对 2026 年取消正常化有信心）；明确 COVID 收入影响极小，且可能有上行。

Q&A Batch (11-13 of 13)

Q11 — Luke Sergott

Topic: Burn rate stability and 2026 outlook
Key points:
- Q4 burn rate implied a slight step-down from the midpoint; year-to-date burn came in slightly better than the expected ~8% stable level.
- Cancels in Q3 skewed disproportionately toward studies not yet started (0% burn rate); gross bookings increase is a near-term drag on burn rate as studies ramp up.
- 2026 burn rate will depend on cancels, gross wins, and initiatives to enhance burn rate; guidance for next year will provide more color later.
Mgmt stance: Neutral — burn rate is around 8% as anticipated, but future trajectory depends on multiple factors (cancels, wins, initiatives) with no specific 2026 guidance yet.

Q12 — Christine Rains

Topic: Early phase vs. late phase work strength
Key points:
- Early phase business continues to show good activity with strong growth on both year-over-year and sequential bases.
- Early phase business grew at double digits year-over-year; management intends to sustain and improve that growth.
Mgmt stance: Bullish — early phase strength is ongoing and management is committed to sustaining double-digit growth.

Q13 — Casey Woodring

Topic: Trial mix driving pass-throughs and automation/AI margin drivers
Key points:
- Higher pass-throughs in Q3 were partly driven by trial mix, including a particularly active COVID/vaccine study; pass-throughs as an increasing proportion of revenue is more about therapeutic mix.
- Automation is a key lever for efficiency; ICON is deploying AI-enabled technologies, including a new end-to-end project management workflow system.
- Proprietary multi-agent digital assistant "Orbis" is being deployed as a front door for employees to access multiple AI agents; early days but expected to create and capture value.
Mgmt stance: Bullish — technology (including AI and agentic AI) is a core part of cost management and value creation, though near-term margin pressure is sustained and technology benefits are organic, not immediate.